The effects of pioglitazone hydrochloride monotherapy on abnormal lipid control were evaluated in Japanese patients with type 2 diabetes mellitus, comparing with glibenclamide monotherapy. Methods: Patients were randomly assigned to receive, once daily, pioglitazone hydrochloride, at 15 mg or 30 mg (n 46), or glibenclamide, at 1.25 mg or 2.5 mg (n 46). The 24-week study included patients with type 2 diabetes having high levels of triglyceride (TG). Results: Pioglitazone hydrochloride produced beneficial effects on dyslipidemia in patients with type 2 diabetes, compared with the baseline and the glibenclamide group, as demonstrated by increases in high-density lipoprotein cholesterol (HDL-C) levels and low-density lipoprotein cholesterol (LDL) particle size, a fall in TG levels, and an increased ratio of visceral to subcutaneous fat volumes (V/S). Pioglitazone hydrochloride reduced fasting serum insulin levels, with low fasting plasma glucose (FPG) and glycohemoglobin levels, compared to the baseline, suggesting an improvement of insulin resistance. Conclusion: As expected, glibenclamide reduced FPG levels through increased insulin secretion. Pioglitazone hydrochloride and glibenclamide were well tolerated. Pioglitazone hydrochloride improved dyslipidemia related to insulin resistance, whereas glibenclamide enhanced insulin secretion, with only a minor effect on lipid control, in Japanese patients with type 2 diabetes. 
Introduction
Type 2 diabetes mellitus is characterized by inadequate insulin secretion and/or insulin resistance 1) . Insulin resistance is associated with impaired glucose tolerance and dyslipidemia, and also might contribute to the pathogenesis of some diseases, such as hypertension and coronary heart diseases [2] [3] [4] . The number of Japanese diabetes patients is estimated as 7.4 million people. East Asian people, especially Japanese, easily develop insulin resistance by a slight increase of viscer-al fat, because in many cases they have less secretory capacity than Westerners; therefore, it is thought that many Japanese type 2 diabetes patients have insulin resistance. Drugs for the treatment of type 2 diabetes mellitus include biguanide, sulphonylurea, and thiozolidinedione, which have different modes of action [5] [6] [7] . Pioglitazone hydrochloride (referred to as pioglitazone) has been found to be efficacious for improving several parameters, including hypertriglyceridemia and hyperinsulinemia in animal models of diabetes mellitus [8] [9] [10] [11] [12] . Accumulating evidence has established that pioglitazone monotherapy [13] [14] [15] [16] , or in combination with other agents having a complementary mode of action 17, 18) , is efficacious for the treatment of patients with type 2 diabetes mellitus.
Glibenclamide has been widely used as a sulphonylurea-class oral hypoglycemic agent, and is the refer-ence drug for comparison with new sulphonylureas 19) . Hypoglycemia is considerably more common with treatment with a long-acting sulphonylurea, such as glibenclamide 5) . There have been no previous adequate and well-controlled clinical trials of pioglitazone and sulphonylureas to examine the effects on lipid metabolism in Japanese patients. In the present study, we evaluated the effects of pioglitazone on dyslipidemia [e.g. high triglyceride (TG) and low high-density lipoprotein cholesterol (HDL-C)], as well as glucose control (e.g. elevated levels of glucose and glycohemoglobin), in comparison with glibenclamide, in a multicenter, randomized, clinical trial.
Subjects
Japanese type 2 diabetes patients between 20 and 79 years of age were eligible for enrollment if they met the following criteria: they had received dietary and exercise instructions, without anti-diabetic and hypolipidemic agents; they had 140 (mg/dL) of fasting plasma glucose (FPG) levels, 80 (mg/dL) of HDL-C levels, and TG levels between 150 (mg/dL) and 500 (mg/dL).
The following patients ware excluded: those taking any medications known to affect glucose metabolism; with a history of ketoacidosis, or with an unstable progressive diabetic coma or pre-coma condition; with impaired liver function, kidney function, abnormal lipid metabolism (nephrotic syndrome, Cushing syndrome, etc.), history of allergy to thiazolizinediones (pioglitazone, troglitazone, etc.), and/or sulfonylurea, tumor therapy, or alcohol abuse; with myocardial infarction or cerebrovascular dysfunction, and receiving insulin because of a severe infection.
Each patient gave written informed consent before entering the clinical trial. Ethical review boards of each participating center approved the study protocol before any patients entered the trial. This study was conducted in compliance with Good Clinical Practice and Good Post-Marketing Surveillance Practice in Japan.
Methods

Study Design
This study was a randomized, multicenter, nonblinded, parallel group of pioglitazone compared to glibenclamide. This study was designed to determine, regarding lipid and glucose levels, the influence of pioglitazone and glibenclamide in Japanese diabetes patients. The primary endpoint was a change from the baseline of lipid parameters (TG and HDL-C). The secondary endpoints were changes from the baseline of low-density lipoprotein cholesterol (LDL) particle size and the ratio of visceral to subcutaneous fat volumes (V/S). During the observation period, laboratory tests were carried out to determine the eligibility of patients. At 18 centers in Japan, of 126 patients with type 2 diabetes screened for eligibility, 92 patients were randomized to receive pioglitazone [15 mg once daily (OD)] or glibenclamide (1.25 mg OD). When the patients had FPG levels 126 (mg/dL) after eight weeks of treatment, the dose of pioglitazone or glibenclamide was increased during the subsequent 9 to 24 weeks to 30 mg OD (15 mg for 0-8 weeks) or 2.5 mg OD (1.25 mg for 0-8 weeks), respectively.
Biochemical Parameters
All laboratory specimens were collected at the participating sites and shipped to a central laboratory (SRL, Inc. Hachioji, Japan) for assay. Fasting serum lipid levels (TG, HDL-C, and LDL-C) were determined by a standard method.
Measurement of Fat Distribution
Distribution between visceral and subcutaneous fat volumes was determined by a modified method of CT scanning. CT images were processed using Fat Scan (N2 System Corporation) by Quintiles Transnational Japan K.K. (Tokyo, Japan). V/S was calculated by dividing the visceral adipose tissue area by the subcutaneous adipose tissue area.
Statistical Analysis
Summary statistics of the change value from the baseline to the end of treatment with HDL-C by each group was calculated, and the difference of the change value between groups was compared using the two sample t -test. TG was analyzed in the same manner as HDL-C.
The primary endpoints of this study were HDL-C and TG. For a multiplicity of primary endpoints, we used a closed testing procedure 20) to adjust the significance level. In the procedure, HDL-C was tested first, and then TG was analyzed as the primary analysis only when the result of HDL-C was significant. If the result of HDL-C was not significant, TG was analyzed only for exploratory analysis. The change value in each group was analyzed using the paired t -test.
Results
At baseline, 92 patients were assigned to receive pioglitazone (n 46) or glibenclamide (n 46). There were no significant differences in the baseline profile between the two groups ( Table 1) . Eighty (39 for pioglitazone and 41 for glibenclamide) of 92 patients (87%) completed the treatment period. The reasons for withdrawal of patients were adverse events [2.6% (n 1) in the pioglitazone group; 7.3% (n 3) in the glibenclamide group], failure to respond to drugs, and such administrative reasons as being lost to follow-up, reversal of the decision to give informed consent, and so on.
Lipid Control
Lipid parameters, including TG, HDL-C, LDL-C, LDL particle size, V/S, and lipoprotein lipase (LPL) protein, at both baseline and end of treatment, are shown in Table 2 and Fig. 1-6 . TG levels were significantly decreased in the pioglitazone group [181.2 95.2 (mg/dL)], compared to baseline [238.9 139.7 (mg/dL)], and changes from baseline in TG levels were more decreased significantly in pioglitazone group than glibenclamide group [pioglitazone, 57.7 111.5 (mg/ dL); glibenclamide, 7.3 112.7 (mg/dL) at 24 weeks only ( Fig. 1)] . On the other hand, HDL-C levels were significantly increased in the pioglitazone group immediately after treatment [53.5 11.8 (mg/dL) at four weeks compared to 50.6 11.9 (mg/dL) at baseline], and the change was maintained up to 24 weeks (Fig. 2) . Pioglitazone caused a marginal increase in LDL cholesterol levels (Fig. 3) , although it was not statistically significant. LDL particle size is reported to be inversely correlated with relative migration (RM) values 21) . RM values were significantly decreased in the pioglitazone group compared to baseline at eight weeks, with a further decrease up to 24 weeks (Fig. 4) . A reduction of RM values in the glibenclamide group was only observed at 24 weeks. V/S was decreased in the pioglitazone group (changes from baseline: 0.10 0.22). The changes from baseline for the pioglitazone group were more decreased significantly than for the glibenclamide group (Fig. 5) , suggesting that pioglitazone produces a shift in fat distribution from visceral to subcutaneous tissues. Moreover, LPL protein levels were significantly increased in the pioglitazone group compared to the glibenclamide group (Fig. 6) . LPL protein levels were measured as preheparin LPL mass 22) , which is the estimated LPL amount 23) . These results suggest that pioglitazone improves dyslipidemia compared with glibenclamide in type 2 diabetes.
Glycemic Control
Effects of pioglitazone on glycemic control were examined in comparison with glibenclamide. At the end of treatment, both pioglitazone and glibenclamide reduced FPG levels compared with baseline ( Table 3) . Glycohemoglobin levels were also decreased in both pioglitazone and glibenclamide groups compared with baseline.
Fasting serum insulin (FSI) levels were significantly increased in the glibenclamide group at the end of treatment compared to baseline ( Table 3) , whereas pioglitazone had no remarkable effect on FSI levels compared to baseline. Moreover, at the end of treatment, pioglitazone had improved insulin resistance, as assessed by homeostasis model assessment of insulin resistance (HOMA-IR) compared with baseline (Table   3) , wheseas it had no remarkable effect on HOMA-IR compared to baseline. These results suggest that pioglitazone produces beneficial effects on insulin resistance, probably resulting in improved lipid control, as well as glycemic control.
Safety
The most frequently reported adverse events were edema (pioglitazone group) and hypoglycemia (glibenclamide group), whereas the incidence of adverse events was similar in the two groups (pioglitazone, 65.2%; glibenclamide, 69.6%).
Discussion
Type 2 diabetes mellitus is characterized by impaired glycemic and lipid control, including high TG and low HDL, which is believed to be closely related to insulin resistance [1] [2] [3] . These metabolic abnormalities are a risk factor for cardiovascular diseases, such as coronary heart disease 2, 4) . Pioglitazone monotherapy or combination therapy has been demonstrated to improve dyslipidemia, to variable extents, in terms of the modulation of TG and/or HDL-C levels in several clinical trials 13, [15] [16] [17] 24) . In the present study, we evaluated the effects of pioglitazone in comparison with glibenclamide on lipid and glycemic control.
High HDL-C is considered to play a role as a negative risk factor against the progression of atherosclerosis, and low HDL-C is a risk factor for cardiovascular diseases 25) . We demonstrated a rise in HDL-C and a fall in TG following pioglitazone treatment (Table 2), consistent with the findings of Arnoff et al. 24) . Pioglitazone-induced changes in LDL levels also had some variations: a rise in some reports 13, 24) , but not in others, including our studies 16, 26) (Table 2 ). In our study, although LDL-C levels were elevated slightly (not statistically significant) in the pioglitazone group, LDL particle size was increased compared to the baseline ( Table 2) , as reported previously 27) . LDL particle size, which is associated with increased risk of cardiovascular diseases 28, 29) , decreases with progression from normal individuals to overt type 2 diabetes 30) . LDL particles are more susceptible to oxidative modification than larger LDL, and oxidized LDL can be taken up by macrophages in vessel endothelial cells, resulting in atherosclerotic plaque formation. These results suggest that pioglitazone might produce favorable effects on early endothelial dysfunction in the vasculature 4) through enlargement of LDL particle size as well as modulation of the HDL-C/TG ratio. In contrast to pioglitazone, glibenclamide had only minor effects on lipid control ( Table 2) . We examined non-HDL-C to estimate the effects of pioglitazone on remnant and IDL; however, non-HDL-C levels did not change significantly in both pioglitazone and glibenclamide groups.
Glibenclamide, a sulphonylurea, functions to stimulate the secretion of insulin from pancreatic cells 5) . FSI levels were substantially increased in the glibenclamide group, compared to baseline, leading to a fall in FPG and glycohemoglobin levels ( Table 3) . In sharp contrast to glibenclamide, pioglitazone significantly reduced FSI levels, accompanied by a fall in FPG levels (Table 3) , which represents improved insulin resistance 3) . The insulin resistance assessed by HOMA-IR in our study 31) was significantly alleviated in the pioglitazone group, compared to baseline, but the difference was not statistically significant (p 0.05), compared with glibenclamide ( Table 3) . The failure to detect a significantly potent effect on insulin resistance in the pioglitazone group, compared to the glibenclamide group, might be due to the limitation of HOMA assessment in a small-scale study, as suggested by Bonora et al. 32) . Although the molecular mechanisms underlying pioglitazone-induced improvement on glycemic control remain largely unresolved, pioglitazone has been demonstrated to enhance glucose uptake in skeletal muscle and adipose tissue, and/or to reduce glucose output from the liver 16) , which might contribute to improve insulin resistance.
According to other studies 13, 15, 16, 33) , weight gain was observed in patients with substantial reduction of glycohemoglobin levels following pioglitazone treatment, despite improving insulin resistance. Since obesity is closely related to insulin resistance 34) , these paradoxical effects of pioglitazone could be explained by the context of the distribution of fat mass. Thus, a shift in fat tissue distribution from visceral to subcutaneous tissues by pioglitazone monotherapy (Fig. 5 ) 8, 26) might contribute to improve insulin resistance. It is of note that pioglitazone preferentially causes terminal differentiation of preadipocytes and lipogenesis in mature adipocytes of subcutaneous, but not visceral, origins [35] [36] [37] . Long-term clinical study is required to address whether pioglitazone-induced weight gain affects insulin resistance.
Although our study design did not allow us to elucidate the molecular mechanisms underlying the pioglitazone-induced beneficial effects, pioglitazone binds to and activates nuclear receptor peroxisome proliferator-activated receptor (PPAR ) to induce the transcription of several genes necessary for lipid and glucose metabolism 6, [38] [39] [40] , which might contribute to improve insulin resistance, associated with dyslipidemia and glycemic control. Pioglitazone and glibenclamide were well tolerated. Regardless of the molecular mechanisms, this clinical trial clearly demonstrates that pioglitazone monotherapy would be efficacious for patients with type 2 diabetes, at least in part, by improving insulin resistance associated with dyslipidemia and glucose control.
